Advice
in the absence of a submission from the holder of the marketing authorisation:
ranibizumab (Lucentis®) is not recommended for use within NHSScotland.
Indication under review: In preterm infants for the treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP (aggressive posterior ROP) disease.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice616KB (PDF)
Medicine details
- Medicine name:
- ranibizumab (Lucentis)
- SMC ID:
- SMC2274
- Indication:
In preterm infants for the treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP (aggressive posterior ROP) disease.
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 09 March 2020